Literature DB >> 11287450

Three-year results of the Finnish prostate cancer screening trial.

L Määttänen1, A Auvinen, U H Stenman, T Tammela, S Rannikko, J Aro, H Juusela, M Hakama.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11287450     DOI： 10.1093/jnci/93.7.552

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  6 in total

1.  Label-Free Impedance Biosensors: Opportunities and Challenges.

Authors:  Jonathan S Daniels; Nader Pourmand
Journal:  Electroanalysis       Date:  2007-05-16       Impact factor: 3.223

2.  Major inter-laboratory variations in PSA testing practices: results from national surveys in Ireland in 2006 and 2007.

Authors:  F J Drummond; L Sharp; H Comber
Journal:  Ir J Med Sci       Date:  2008-10-08       Impact factor: 1.568

3.  Proteomics and mass spectrometry for cancer biomarker discovery.

Authors:  Ming Lu; Kym F Faull; Julian P Whitelegge; Jianbo He; Dejun Shen; Romaine E Saxton; Helena R Chang
Journal:  Biomark Insights       Date:  2007-10-03

4.  Usefulness of Total PSA Value in Prostate Diseases Diagnosis.

Authors:  Alden Prcic; Edin Begic; Mustafa Hiros
Journal:  Acta Inform Med       Date:  2016-06-04

5.  Prostate Cancer Screening with PSA: Ten Years' Experience of Population Based Early Prostate Cancer Detection Programme in Lithuania.

Authors:  Ausvydas Patasius; Agne Krilaviciute; Giedre Smailyte
Journal:  J Clin Med       Date:  2020-11-26       Impact factor: 4.241

6.  Sojourn-time-corrected receiver operating characteristic curve (ROC) for prostate specific antigen (PSA) test in population-based prostate cancer screening.

Authors:  Hsiao-Hsuan Jen; Wei-Jung Chang; Chen-Yang Hsu; Amy Ming-Fang Yen; Anssi Auvinen; Tony Hsiu-Hsi Chen; Sam Li-Sheng Chen
Journal:  Sci Rep       Date:  2020-11-26       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.